We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid, Highly Accurate Test Developed to Detect Viruses

By LabMedica International staff writers
Posted on 16 Dec 2021
Print article
Image: Schematic diagram of the Plasmonic Biosensor that detects virus biomarkers from the blood (Photo courtesy of University of Central Florida)
Image: Schematic diagram of the Plasmonic Biosensor that detects virus biomarkers from the blood (Photo courtesy of University of Central Florida)
The rapid spread of viral infections demands early detection strategies to minimize proliferation of the disease. A device has been developed that detects viruses in the body as fast as and more accurately than current, commonly used rapid detection tests.

The optical sensor device uses nanotechnology to accurately identify viruses in seconds from blood samples. The device works by using nano-scale patterns of gold that reflect back the signature of the virus it is set to detect in a sample of blood. Different viruses can be detected by using different DNA sequences that selectively target specific viruses.

Bioengineers from the University of Central Florida (Orlando, FL, USA), who developed the device, demonstrated a plasmonic biosensor to detect Dengue virus, a mosquito transmitted pathogen that causes Dengue fever, which was chosen as a model, via its nonstructural protein NS1 biomarker. The sensor is functionalized with a synthetic single-stranded DNA oligonucleotide and provides high affinity toward NS1 protein present in the virus genome.

The scientist reported that the device can tell with 95% accuracy if someone has a virus, a significant improvement over current rapid tests that experts warn could have low accuracy. Testing for viruses is important for early treatment and to help stop their spread. They demonstrated the detection of NS1 protein at a concentration of 0.1–10 μg/mL in bovine blood using an on-chip microfluidic plasma separator integrated with the plasmonic sensor which covers the clinical threshold of 0.6 μg/mL of high risk of developing Dengue hemorrhagic fever. The device closely matches the accuracy of the gold-standard PCR-based tests, but with nearly instantaneous results instead of results that take several days to receive.

Debashis Chanda, PhD, a Professor of Nanoscience Technology and senior author of the study, said, “The sensitive optical sensor, along with the rapid fabrication approach used in this work, promises the translation of this promising technology to any virus detection including COVID-19 and its mutations with high degree of specificity and accuracy. We have demonstrated a credible technique which combines PCR-like genetic coding and optics on a chip for accurate virus detection directly from blood.”

The authors concluded that the conceptual and practical demonstration shows the translation feasibility of these microfluidic optical biosensors for early detection of a wide range of viral infections, providing a rapid clinical diagnosis of infectious diseases directly from minimally processed biological samples at point of care locations. The study was originally published on September 8, 2021 in the journal Nano Letters.

Related Links:
University of Central Florida

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.